Gateway VCT previously had a remit to build a portfolio of early and later stage technology and technology related businesses, including life science companies. Aberdeen intends to adopt a new approach and, subject to available liquidity, invest the fund alongside its other VCTs in most of its deals, which are spread across a wider range of sectors and are typically in larger, later-stage businesses that have already demonstrated potential for growth.